ProSciento Prepares to ‘Step Out’ Against Diabetes as a Sponsor for the American Diabetes Association Event in Southern California for a 19th Year

SAN DIEGO, September 16, 2023 – ProSciento, Inc., the leading clinical research organization (CRO) for metabolic diseases, celebrates its 19th year as a corporate sponsor of Step Out: Walk to Stop Diabetes, hosted by the American Diabetes Association (ADA). ADA Step Out Walks brings together thousands of walkers in events across the nation to raise awareness, support research, and fund programs for individuals affected by type 1 and type 2 diabetes.

This year ProSciento is also pleased to be the Living Red Sponsor for the Step Out event in Southern California. The ADA’s Living Red initiative recognizes and supports individuals living with diabetes (Red Striders) participating in the events, recognizable in their distinct red jerseys.

The Southern California event takes place Saturday, September 30 at Rainbow Lagoon, 400 East Shoreline Drive in Long Beach. Look for ProSciento’s tent in the Wellness Village and come by to visit our photo booth and meet our representatives.

About ProSciento, Inc.

ProSciento is the leading provider of clinical research and patient engagement solutions for metabolic continuum diseases with unparalleled expertise in diabetes, obesity, and steatotic liver disease. As a full-service clinical research organization (CRO), ProSciento works with clients across the globe to design and conduct multinational clinical trials, from early clinical development planning through phase III. With two decades as a leading scientific contributor to metabolic continuum research, ProSciento has built trusted relationships with clients, partners, and patients, supporting the development of therapeutics and devices that make an important difference in the lives of individuals with metabolic diseases. For more information, please visit

For general inquiries, please contact:

Abby Devine, Senior Director, Corporate Communications, ProSciento, Inc.

For clinical trial enrollment inquires, please visit or email